HC Wainwright Issues Negative Outlook for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Stock analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Adherex Technologies in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.12 per share for the quarter, down from their previous forecast of $0.19. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.16 EPS, Q3 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.30 EPS and FY2027 earnings at $0.96 EPS.

A number of other equities analysts have also weighed in on FENC. B. Riley Financial started coverage on shares of Adherex Technologies in a report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target on the stock. Wall Street Zen downgraded Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, January 22nd. Piper Sandler began coverage on Adherex Technologies in a research report on Friday, January 9th. They set an “overweight” rating and a $18.00 price target for the company. Finally, Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.25.

Adherex Technologies Stock Performance

Adherex Technologies stock opened at $6.41 on Tuesday. Adherex Technologies has a 1 year low of $4.68 and a 1 year high of $9.92. The firm has a 50 day moving average price of $7.75 and a 200 day moving average price of $8.03. The company has a market cap of $220.95 million, a price-to-earnings ratio of -18.85 and a beta of 0.93.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.21). Adherex Technologies had a negative return on equity of 183.18% and a negative net margin of 22.62%.The company had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.75 million.

Insider Transactions at Adherex Technologies

In other Adherex Technologies news, Director Rosty Raykov sold 10,349 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $7.76, for a total value of $80,308.24. Following the transaction, the director directly owned 98,477 shares of the company’s stock, valued at $764,181.52. This trade represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,897 shares of the company’s stock, valued at approximately $66,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Key Headlines Impacting Adherex Technologies

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: HC Wainwright projects strong longer‑term profitability, forecasting FY2027 EPS of $0.96 and several positive quarterly EPS estimates for 2027 — a bullish long‑term signal for growth expectations. Read More.
• Positive Sentiment: Street consensus remains constructive — analysts have issued a “Moderate Buy” recommendation on FENC, which can support demand for the shares. Read More.
• Neutral Sentiment: The company granted inducement stock options (ISOs) to 24 new non‑executive employees totaling 377,500 shares under its 2026 Inducement Plan; this is intended to attract talent but introduces potential dilution over time. Read More.
• Negative Sentiment: Recent quarterly results disappointed: Adherex reported a ($0.17) EPS vs. consensus +$0.04 and revenue of $13.78M vs. $14.75M expected — a clear near‑term negative that can pressure the stock. Read More.
• Negative Sentiment: HC Wainwright trimmed several near‑term estimates (multiple 2026 quarters and FY2026 EPS cut from $0.64 to $0.31) — the broker lowered short‑term expectations even while keeping a more optimistic FY2027 view, creating mixed signals that can add volatility. Read More.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.